MedTrace Logo

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study

NCT03710252 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-10-18

No results posted yet for this study

Summary

This is a Phase IV, open label, single center study of OBV/PTV/r + DSV +/- RBV for 12 or 24 weeks for the treatment of chronic HCV-1 infection in a real world urban clinical setting.

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

paritaprevir/ritonavir/ombitasvir + dasabuvir +/- ribavirin

OMB/PTV/r + DSV +/- RBV

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • American Research Corporation

    lead NETWORK

Principal Investigators

  • Fred Poordad, MD · American Research Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-09-30
Completion
2017-09-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03710252 on ClinicalTrials.gov